Sawyer & Company Inc Grows Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Sawyer & Company Inc lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 0.5% in the 3rd quarter, Holdings Channel.com reports. The firm owned 15,939 shares of the medical research company’s stock after purchasing an additional 77 shares during the period. Amgen comprises about 1.9% of Sawyer & Company Inc’s holdings, making the stock its 16th largest position. Sawyer & Company Inc’s holdings in Amgen were worth $5,136,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. GLOBALT Investments LLC GA acquired a new position in shares of Amgen during the fourth quarter worth about $3,222,000. American Trust purchased a new position in shares of Amgen during the fourth quarter valued at approximately $358,000. Chicago Partners Investment Group LLC lifted its stake in shares of Amgen by 1.3% during the fourth quarter. Chicago Partners Investment Group LLC now owns 4,543 shares of the medical research company’s stock valued at $1,388,000 after buying an additional 57 shares during the period. Transcendent Capital Group LLC acquired a new position in Amgen during the fourth quarter worth approximately $81,000. Finally, Northwest Bank & Trust Co acquired a new position in Amgen during the fourth quarter worth approximately $576,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on AMGN shares. Morgan Stanley dropped their price objective on shares of Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a research report on Thursday, July 11th. TD Cowen boosted their target price on shares of Amgen from $360.00 to $381.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $305.00 target price (down from $310.00) on shares of Amgen in a report on Wednesday, August 7th. Cantor Fitzgerald began coverage on shares of Amgen in a report on Friday, September 27th. They set an “overweight” rating and a $405.00 price target on the stock. Finally, Oppenheimer reissued an “outperform” rating and issued a $380.00 target price on shares of Amgen in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $326.30.

Amgen Price Performance

NASDAQ:AMGN traded up $7.34 during mid-day trading on Friday, reaching $328.35. 1,567,233 shares of the company were exchanged, compared to its average volume of 2,466,783. Amgen Inc. has a 12 month low of $249.70 and a 12 month high of $346.85. The company has a fifty day moving average of $326.06 and a 200 day moving average of $310.75. The company has a quick ratio of 0.89, a current ratio of 1.26 and a debt-to-equity ratio of 9.64. The stock has a market cap of $176.14 billion, a PE ratio of 46.91, a PEG ratio of 2.86 and a beta of 0.61.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). Amgen had a return on equity of 161.72% and a net margin of 10.12%. The company had revenue of $8.39 billion for the quarter, compared to the consensus estimate of $8.35 billion. During the same period in the prior year, the company earned $5.00 EPS. The firm’s revenue was up 20.1% compared to the same quarter last year. On average, research analysts anticipate that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Stockholders of record on Friday, August 16th were paid a $2.25 dividend. This represents a $9.00 annualized dividend and a dividend yield of 2.74%. The ex-dividend date of this dividend was Friday, August 16th. Amgen’s dividend payout ratio (DPR) is presently 128.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.